Similarly, the CALGB/SWOG 80405 trial showed overall improved outcomes, especially in left-sided primary KRAS wt CRC with improved OS (OS for all-sided lesions was 30 months with cetuximab plus chemotherapy versus 29 months with bevacizumab plus chemotherapy, the finding was not statistically significant) in this population [42,43]. Here, KRAS is linked to colorectal carcinoma.